Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1960 1
1990 1
1991 1
1994 1
1995 4
1996 2
1997 5
1998 1
1999 2
2000 2
2001 2
2002 1
2003 3
2004 2
2005 5
2006 3
2007 1
2008 5
2009 2
2010 3
2011 5
2012 4
2013 3
2014 2
2015 4
2016 6
2017 2
2018 4
2019 2
2020 4
2021 1
2022 2
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
King LDW, Pulido D, Barrett JR, Davies H, Quinkert D, Lias AM, Silk SE, Pattinson DJ, Diouf A, Williams BG, McHugh K, Rodrigues A, Rigby CA, Strazza V, Suurbaar J, Rees-Spear C, Dabbs RA, Ishizuka AS, Zhou Y, Gupta G, Jin J, Li Y, Carnrot C, Minassian AM, Campeotto I, Fleishman SJ, Noe AR, MacGill RS, King CR, Birkett AJ, Soisson LA, Long CA, Miura K, Ashfield R, Skinner K, Howarth MR, Biswas S, Draper SJ. King LDW, et al. Among authors: birkett aj. Cell Rep Med. 2024 Jul 16;5(7):101654. doi: 10.1016/j.xcrm.2024.101654. Cell Rep Med. 2024. PMID: 39019011 Free PMC article.
M2e-based universal influenza A vaccine.
Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X. Fiers W, et al. Among authors: birkett a. Vaccine. 2009 Oct 23;27(45):6280-3. doi: 10.1016/j.vaccine.2009.07.007. Vaccine. 2009. PMID: 19840661 Review.
A research agenda for malaria eradication: vaccines.
malERA Consultative Group on Vaccines. malERA Consultative Group on Vaccines. PLoS Med. 2011 Jan 25;8(1):e1000398. doi: 10.1371/journal.pmed.1000398. PLoS Med. 2011. PMID: 21311586 Free PMC article. Review.
A "universal" human influenza A vaccine.
Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. Fiers W, et al. Among authors: birkett a. Virus Res. 2004 Jul;103(1-2):173-6. doi: 10.1016/j.virusres.2004.02.030. Virus Res. 2004. PMID: 15163506 Review.
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype.
Barrett JR, Pipini D, Wright ND, Cooper AJR, Gorini G, Quinkert D, Lias AM, Davies H, Rigby CA, Aleshnick M, Williams BG, Bradshaw WJ, Paterson NG, Martinson T, Kirtley P, Picard L, Wiggins CD, Donnellan FR, King LDW, Wang LT, Popplewell JF, Silk SE, de Ruiter Swain J, Skinner K, Kotraiah V, Noe AR, MacGill RS, King CR, Birkett AJ, Soisson LA, Minassian AM, Lauffenburger DA, Miura K, Long CA, Wilder BK, Koekemoer L, Tan J, Nielsen CM, McHugh K, Draper SJ. Barrett JR, et al. Among authors: birkett aj. Cell. 2024 Sep 5;187(18):4964-4980.e21. doi: 10.1016/j.cell.2024.06.015. Epub 2024 Jul 25. Cell. 2024. PMID: 39059380 Free article.
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.
Williams BG, King LDW, Pulido D, Quinkert D, Lias AM, Silk SE, Ragotte RJ, Davies H, Barrett JR, McHugh K, Rigby CA, Alanine DGW, Barfod L, Shea MW, Cowley LA, Dabbs RA, Pattinson DJ, Douglas AD, Lyth OR, Illingworth JJ, Jin J, Carnrot C, Kotraiah V, Christen JM, Noe AR, MacGill RS, King CR, Birkett AJ, Soisson LA, Skinner K, Miura K, Long CA, Higgins MK, Draper SJ. Williams BG, et al. Among authors: birkett aj. Nat Commun. 2024 Jun 7;15(1):4857. doi: 10.1038/s41467-024-48721-3. Nat Commun. 2024. PMID: 38849365 Free PMC article.
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults.
van der Boor SC, Smit MJ, van Beek SW, Ramjith J, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Pickkers P, Wu Y, Locke E, Lee SM, Aponte J, King CR, Birkett AJ, Miura K, Ayorinde MA, Sauerwein RW, Ter Heine R, Ockenhouse CF, Bousema T, Jore MM, McCall MBB. van der Boor SC, et al. Among authors: birkett aj. Lancet Infect Dis. 2022 Nov;22(11):1596-1605. doi: 10.1016/S1473-3099(22)00428-5. Epub 2022 Aug 10. Lancet Infect Dis. 2022. PMID: 35963275 Free PMC article. Clinical Trial.
Vaccines to Accelerate Malaria Elimination and Eventual Eradication.
Healer J, Cowman AF, Kaslow DC, Birkett AJ. Healer J, et al. Among authors: birkett aj. Cold Spring Harb Perspect Med. 2017 Sep 1;7(9):a025627. doi: 10.1101/cshperspect.a025627. Cold Spring Harb Perspect Med. 2017. PMID: 28490535 Free PMC article. Review.
A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.
Birkett A, Lyons K, Schmidt A, Boyd D, Oliveira GA, Siddique A, Nussenzweig R, Calvo-Calle JM, Nardin E. Birkett A, et al. Infect Immun. 2002 Dec;70(12):6860-70. doi: 10.1128/IAI.70.12.6860-6870.2002. Infect Immun. 2002. PMID: 12438363 Free PMC article.
87 results